Tirzepatide + BPC-157: the stack guide
Tirzepatide with BPC-157 is a fat-loss-plus-gut-protection pair. GLP-1/GIP dual agonists frequently cause nausea, constipation, and GI irritation during titration — BPC-157 is widely used alongside them to blunt those gut side effects and protect the stomach lining.
Why Tirzepatide and BPC-157 pair well
Tirzepatide drives the weight-loss mechanism (slowed gastric emptying, appetite suppression, improved insulin sensitivity). BPC-157 supports gastric and intestinal tissue integrity — animal data shows it accelerates healing of gastric ulcers and reduces NSAID-induced gut damage. The combination preserves Tirzepatide efficacy while softening its most-cited drawback.
Suggested cadence
Tirzepatide follows the standard titration (2.5 mg → 5 mg → 7.5 mg → 10 mg weekly, with further steps up to 15 mg). BPC-157 250–500 mcg subcutaneous daily during titration weeks, often reduced to 2–3× weekly once GI tolerance stabilizes.
This is informational only — dosing should always be individualized and discussed with a qualified clinician.
Reconstitution notes
Tirzepatide: A common ratio is 2 ml of bacteriostatic water for a 10 mg vial. Open the Tirzepatide calculator →
BPC-157: A common ratio is 2 ml of bacteriostatic water for a 5 mg vial. Open the BPC-157 calculator →
Side effects to watch for
Do not use BPC-157 to push through severe or persistent Tirzepatide side effects — those warrant a dose hold or reduction. BPC-157 is research-use only in the US. Both compounds share injection-site reactions as the most common minor complaint.
The two compounds
Track this stack on iPhone
Peptide Protocol schedules both compounds, calculates reconstitution, and rotates injection sites automatically.
See the app →Frequently asked questions
Why stack Tirzepatide with BPC-157?
Tirzepatide with BPC-157 is a fat-loss-plus-gut-protection pair. GLP-1/GIP dual agonists frequently cause nausea, constipation, and GI irritation during titration — BPC-157 is widely used alongside them to blunt those gut side effects and protect the stomach lining.
What is the typical Tirzepatide + BPC-157 dose?
Tirzepatide follows the standard titration (2.5 mg → 5 mg → 7.5 mg → 10 mg weekly, with further steps up to 15 mg). BPC-157 250–500 mcg subcutaneous daily during titration weeks, often reduced to 2–3× weekly once GI tolerance stabilizes.
Can you inject Tirzepatide and BPC-157 in the same syringe?
Many users co-administer GHRH + GHRP pairs (like CJC-1295 + Ipamorelin) in a single syringe to reduce injections, since both are stable in bacteriostatic water for short periods. For other pairs, draw and inject separately to minimize compatibility risk and to attribute any reaction to the correct compound.
What side effects should I watch for?
Do not use BPC-157 to push through severe or persistent Tirzepatide side effects — those warrant a dose hold or reduction. BPC-157 is research-use only in the US. Both compounds share injection-site reactions as the most common minor complaint.
How long should a Tirzepatide + BPC-157 cycle run?
Most user-reported cycles run 4–12 weeks depending on the goal. GH-axis stacks are typically cycled with a break of 4 weeks or more between blocks to preserve receptor sensitivity. Soft-tissue stacks are usually run continuously until the injury resolves.
Educational use only. Peptide Protocol is an informational tool. Nothing on this page constitutes medical advice. Many peptides are prescription-only or restricted in your jurisdiction. Always consult a licensed healthcare professional before injecting any compound.